Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized double-blind placebo-controlled phase III study of Landiolol Hydrochloride for perioperative tachyarrhythmias
CTR20244636Phase 3Active
- Sponsor
- Chengdu Easton Biopharmaceuticals Co., Ltd.
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of landiolol in Atrial fibrillation (AFib), atrial flutter (AFL), sinus tachycardia (ST), tachyarrhythmia, sponsored by Chengdu Easton Biopharmaceuticals Co., Ltd.. Started Dec 2024; status: active.
02
Drugs
landiolol
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)sinus tachycardia (ST)tachyarrhythmia
Beyond the preview
Go deeper on CTR20244636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244636.